clinical trial · NCT06987643
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
EIP Pharma Inc·phase2·recruiting·n = 90
Moderate to Severe Acute Ischaemic StrokeIschaemic StrokeNeflamapimodPlacebo
brief summary
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
started
Jun 20, 2025
primary completion
May 31, 2026
completion
Jun 28, 2026
last updated
Feb 9, 2026
official title
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol